What Teokap-SR Treats: Main Uses and Benefits

Teokap-SR is generally used to provide supportive symptomatic relief across several key therapeutic areas, particularly for supporting the management of symptoms that can interfere with daily functioning. This class of medication is utilized to help with symptoms such as wheezing, shortness of breath, and chest tightness associated with chronic lung diseases.

---

Easing Sudden and Intensifying Symptom Discomfort

This medicine is commonly used to help with symptom clusters that may become intense or disruptive, particularly those related to heightened physiological activity. It is applied across domains where short-term symptomatic support is needed, providing support that helps ease the overall symptom burden during flare-ups.

---

Supporting Management of Episodic Conditions

Teokap-SR is relevant in conditions characterized by periods of heightened symptoms or those involving recurrent or episodic manifestations. It supports the patient during difficult episodes and assists with maintaining functional stability when symptoms create noticeable physiological strain.

---

Quick Fact: Relief for Wheezing and Shortness of Breath

Regulatory References

1. NIH MedlinePlus overview of Theophylline

Who Can and Cannot Use Teokap-SR

The eligibility to use Teokap-SR (Theophylline) is defined by official regulatory documents based on patient health status and age.

---

Absolute Contraindications

Teokap-SR is contraindicated and must not be used by patients with a known hypersensitivity to any Xanthine derivative, those with active peptic ulcer disease, or those with an existing seizure disorder or history of seizures. It is also contraindicated in specific severe cardiac conditions where myocardial stimulation is judged to be harmful.

---

Conditional Use and Restrictions

Use is generally permitted for adults and adolescents. However, several populations require caution and close monitoring due to altered drug clearance, which increases the risk of toxicity:

• Hepatic Impairment: Patients with liver disease (e.g., cirrhosis or acute hepatitis) experience significantly reduced drug clearance.
• Age Extremes: Use in older adults (ge 60 years) and children younger than one year requires strict monitoring due to potential for slower clearance and increased sensitivity.
• Pregnancy and Lactation: The medicine is FDA Pregnancy Category C and is excreted into human milk. Use is conditional and should only occur if the potential benefit outweighs the potential risk.

Interactions with other medicines and products

The interaction profile for Teokap-SR (Theophylline) is predominantly defined by its susceptibility to pharmacokinetic changes (alterations in hepatic clearance) and the presence of severe pharmacodynamic interaction risks, as documented in regulatory information. All listed interactions are strictly based on government-approved prescribing labels.

---

Pharmacokinetic Interactions (Altered Clearance)

Teokap-SR is primarily metabolized by the CYP1A2 enzyme. Co-administration with certain agents may significantly alter its plasma concentration:

• Reduced Theophylline Clearance (Increased Exposure): This is documented with agents that inhibit CYP1A2, such as Ciprofloxacin, Cimetidine, and Zileuton. Non-drug factors like cessation of smoking, a sustained fever (102°F or higher), and hepatic impairment (liver disease) also officially reduce clearance.

• Increased Theophylline Clearance (Reduced Exposure): This occurs with CYP1A2 inducers like Phenytoin and Rifampin, as well as the herbal product St. John’s Wort.

Pharmacodynamic and Contraindicated Combinations

Specific combinations are classified as either contraindicated or not recommended:

• Contraindicated Combinations: Co-administration with Riociguat is contraindicated due to the risk of additive hypotension, and Febuxostat is prohibited as it significantly reduces theophylline metabolism.

• Other Interactions: Theophylline is documented to antagonize the sedative effects of benzodiazepines. Co-administration with Bupropion is noted for increasing the risk of a lowered seizure threshold.

The physiological effect of Teokap-SR is derived from the multifaceted action of theophylline, which modulates key cellular signaling enzymes and receptors to influence muscle tone and cellular inflammation.

Modulation of Intracellular Enzymes

Theophylline primarily acts by non-selectively inhibiting Phosphodiesterase (PDE) enzymes within muscle cells, particularly the PDE3 and PDE4 isoforms. This inhibition prevents the breakdown of the vital intracellular messenger, cAMP, causing its concentration to rise. This molecular cascade leads to the relaxation of the smooth muscle tissue, which mechanically widens the bronchial diameter.

Receptor Antagonism and Gene Transcription Modulation

The drug also exerts effects outside of direct enzymatic inhibition. It functions as a non-selective antagonist of Adenosine Receptors (A1 and A2B), attenuating the release of endogenous mediators that promote muscle contraction and cellular activation. Furthermore, it supports the functional activation of Histone Deacetylase 2 (HDAC2), a nuclear enzyme that suppresses the transcription of genes responsible for creating pro-inflammatory proteins, thereby contributing to the modulation of pro-inflammatory gene expression.

These actions collectively alter physiological dynamics, including modulation of airway responsiveness and **increase in respiratory muscle contractility.

How to Use Teokap-SR

This section outlines the general principles and administration constraints for Teokap-SR (Theophylline Sustained-Release), focusing on usage patterns and dosing requirements.

Official Administration Guidelines

Entity	Detail
Route of Administration	The medication is designed solely for oral use, consistent with the sustained-release capsule formulation.
Dosing Schedule	The dosage is highly individualized and is guided by the measurement of serum theophylline concentrations, with a target therapeutic range of 10 to 15 mu g/mL. The typical maintenance dose for adults ranges from 400 to 600 mg total daily dose.
Frequency Pattern	The medicine is taken either once daily (q24h) or twice daily (q12h), depending on the specific formulation and patient regimen, requiring administration at a consistent time each day.
Preparation Requirements	Extended-release capsules or tablets must be swallowed whole to ensure the proper slow release of the active ingredient. The capsule contents should not be broken, crushed, or chewed.

---

Procedural Context and Special Use Rules

Administration of theophylline requires specific procedural steps beyond simple ingestion. Dose adjustments, whether increases or decreases, must be made in intervals of no less than three days to allow serum concentrations to reach a steady state, reflecting the drug's long half-life. Doses calculated on a milligram-per-kilogram basis should be based on a patient's ideal bodyweight.

For older adults (over 60 years of age), a cautious approach is often utilized, with recommendations for a maximum total daily dose of 400 mg due to potentially reduced drug clearance. This continuous administration is intended for long-term therapy to maintain stable blood levels.

Research evidence / Overview of studies for Teokap-SR

The following information summarizes the scientific research landscape for the active ingredient in Teokap-SR (theophylline), based on findings from randomized controlled trials (RCTs), systematic reviews, and regulatory submissions. This overview describes what types of studies exist and what their findings indicate, without offering any clinical advice or interpretation.

---

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Research has explored the use of this medicine in conditions characterized by functional limitations, such as Chronic Obstructive Pulmonary Disease (COPD). Studies utilized Randomized Controlled Trials (RCTs) to examine outcomes related to physiological strain and patient-reported discomfort. Researchers monitored objective measures like lung function (such as FEV1 and FVC) and blood gas parameters. The findings describe patterns observed in the studies related to changes measured in these core metrics. However, studies monitored patient-reported outcomes describing perceived discomfort, and findings were mixed concerning functional capacity and quality of life scores.

Long-term effects are not fully established for this indication. Many contributing trials are older, and results apply only to the studied populations. Sample sizes were modest in numerous reviews, and certainty remains low regarding the consistency of patient-reported outcomes over extended periods.

---

Evidence for use in Chronic Asthma and Nocturnal Symptoms

Research examined the use of theophylline in Chronic Asthma, focusing on conditions with fluctuating symptoms, such as nocturnal asthma. Studies utilized short-term, double-blind RCTs to observe responses over defined time intervals. Research monitored changes in pulmonary function, especially morning measures, and outcomes describing episodic changes, such as the frequency of nocturnal symptoms.

Studies reported patterns indicating a change in morning lung function and changes measured in the frequency of nocturnal symptoms. However, research exploring temporary physiological imbalance also described instances where subjective reports of fewer nocturnal symptoms were noted alongside objective measurements indicating that sleep quality metrics were not uniformly characterized.

---

Long-term Studies, Specific Populations, and Uncertainty

Research has explored effects over different time periods, including observational studies that monitored patient cohorts for several years to track mortality patterns. However, follow-up durations were limited in the majority of randomized trials, meaning the research provides limited information for long-term outcomes. Theophylline was primarily evaluated in adults, and the results apply only to the populations studied. Data for certain groups, such as children, pregnant women, or specific comorbidity-defined populations, remain insufficient or limited.

The evidence quality varies across studies, contributing to some mixed findings regarding functional and patient-reported outcomes. Research is ongoing to further explore the research base of theophylline, and certainty remains low for some of the effects on patient-reported measures like quality of life.

How to Store and Dispose of Teokap-SR?

Teokap-SR (Theophylline Extended-Release Tablets) must be stored at Controlled Room Temperature (CRT), maintaining a range of 20°C to 25°C (68°F to 77°F). Allowable temperature excursions are between 15°C and 30°C. The medication must be kept in a tightly closed container and stored in a location that is strictly out of the reach of children.

For disposal of unused or expired medicine, general government guidelines should be followed if a drug take-back program is not available. The medicine should be removed from its container, mixed with an undesirable substance like kitty litter or used coffee grounds, and then placed in a sealed container before discarding in the household trash. It is important to scratch out all identifying information on the prescription label before disposal.